Cancers, Vol. 10, Pages 155: Targeted Tumor Therapy Remixed —An Update on the Use of Small-Molecule Drugs in Combination Therapies

Cancers, Vol. 10, Pages 155: Targeted Tumor Therapy Remixed—An Update on the Use of Small-Molecule Drugs in Combination Therapies Cancers doi: 10.3390/cancers10060155 Authors: Martina V. Gatzka Over the last decade, the treatment of tumor patients has been revolutionized by the highly successful introduction of novel targeted therapies, in particular small-molecule kinase inhibitors and monoclonal antibodies, as well as by immunotherapies. Depending on the mutational status, BRAF and MEK inhibitor combinations or immune checkpoint inhibitors are current first-line treatments for metastatic melanoma. However, despite great improvements of survival rates limitations due to tumor heterogeneity, primary and acquired therapy resistance, immune evasion, and economical considerations will need to be overcome. Accordingly, ongoing clinical trials explore the individualized use of small-molecule drugs in new targeted therapy combinations based on patient parameters and tumor biopsies. With focus on melanoma therapy this review aims at providing a comprehensive overview of such novel alternative and combinational therapy strategies currently emerging from basic research. The molecular principles and drug classes that may hold promise for improved tumor therapy combination regimens including kinase inhibition, induction of apoptosis, DNA-damage response inhibition, epigenetic reprogramming, telomerase inhibition, redox modulation, metabolic reprogramming, proteasome inhibition...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research